Skip to main content

Table 2 Frequency of HIV-1 subtypes and mutations associated with drug-resistance in drug-naïve individuals from Paraná State, Brazil, 2010-2013

From: Moderate prevalence of HIV-1 transmitted drug resistance mutations in southern Brazil

 

Recent group (n = 15)

Chronic group (n = 135)

All (n = 150)

Subtype a

B

10 (66.7; 41.7 to 84.8)

71 (52.6; 44.2 to 60.8)

81 (54.0; 46.0 to 61.8)

C

4 (26.7; 10.9 to 52.0)

36 (26.7; 19.9 to 34.7)

40 (26.7; 20.2 to 34.3)

F

0 (0.0; 0.0 to 20.4)

10 (7.4; 4.1 to 13.1)

10 (6.7; 3.7 to 11.8)

CRFs

1 (6.7; 1.2 to 29.8)

18 (13.3; 8.6 to 20.1)

19 (12.7; 8.3 to 18.9)

Resistance mutations by class b

PR region with PI mutation

0 (0.0; 0.0 to 20.4)

1 (0.7; 0.1 to 4.1)

1 (0.7; 0.1 to 3.7)

RT region with NRTI mutation

1 (6.7; 1.2 to 29.8)

3 (2.2; 0.8 to 6.3)

4 (2.7; 1.0 to 6.7)

RT region with NNRTI mutation

1 (6.7; 1.2 to 29.8)

4 (3.0; 1.2 to 7.4)

5 (3.3; 1.4 to 7.6)

Any resistance mutation

2 (13.3; 3.7 to 37.9)

8 (5.9; 3.0 to 11.3)

10 (6.7; 3.7 to 11.8)

  1. Results are presented as N (%; 95% CI). HIV-1, human immunodeficiency virus type 1; PR, protease; RT, reverse transcriptase; PI, protease inhibitors; NRTI, nucleoside analogue reverse transcriptase inhibitor; NNRTI, non-nucleoside analogue reverse transcriptase inhibitors
  2. aComparisons performed using two-tailed Chi square test with confidence interval of 95%
  3. bComparisons performed using two-tailed Fisher’s exact test with confidence interval of 95%
  4. All comparisons had p values > 0.05